Can Nutritional Supplementation Increase the Risk of Crizotinib-Associated Hepatotoxicity: A Clinical Case Example

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death. The identification of oncogenetic driver mutation in lung cancer led to a therapeutic revolution by the discovery of targetable genetic alterations including the anaplasic lymphoma kinase (ALK) fusion oncogene and ROS1 . The tyrosine kinase inhibitor “Crizotinib” improved clinical outcome and prolonged responses. Severe hepatotoxicity is a rare adverse event .We report a case of Crizotinib-induced acute hepatitis with a probable drug-bergamot interaction